Risk of cardiovascular diseases associated with oral progestagen preparations with therapeutic indications

Data from the WHO Collaborative Study suggest that use of progestagen preparations with therapeutic indications are associated with a significantly increased risk of venous thromboembolism but not stroke or myocardial infarction.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The Lancet (British edition) 1999-11, Vol.354 (9190), p.1610-1610
Hauptverfasser:	Poulter, NR, Chang, CL, Farley, TMM, Meirik, O
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Biological and medical sciences Cardiovascular disease Cardiovascular diseases Case-Control Studies Contraceptives, Oral, Synthetic - adverse effects Drug therapy Female Genital system. Reproduction Health risk assessment Health risks Hormones Humans Logistic Models Medical sciences Middle Aged Myocardial infarction Myocardial Infarction - chemically induced Odds Ratio Pharmacology. Drug treatments Progesterone Congeners - adverse effects Progesterone Congeners - therapeutic use Risk Factors Stroke - chemically induced Thromboembolism Thromboembolism - chemically induced Women World Health Organization
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Data from the WHO Collaborative Study suggest that use of progestagen preparations with therapeutic indications are associated with a significantly increased risk of venous thromboembolism but not stroke or myocardial infarction.
ISSN:	0140-6736 1474-547X
DOI:	10.1016/S0140-6736(99)03132-3